Table 1.

Mean CHADS2 score, proportion of patients with prior stroke, and dosing regimen in the trials analyzed by Yoshioka et al

TrialOral FXa inhibitorsRegimenMean CHADS2 scoreProportion of patients with prior stroke, %
J-ROCKET AF22  Rivaroxaban 15 mg once per d 3.3 64 
ROCKET AF24  Rivaroxaban 20 mg once per d 3.5 55 
ENGAGE20  Edoxaban 60 mg once per d 2.8 28 
ARISTOTLE21  Apixaban 5 mg twice per d 2.1 19 
AVERROES19  Apixaban 5 mg twice per d 2.0 14 
TrialOral FXa inhibitorsRegimenMean CHADS2 scoreProportion of patients with prior stroke, %
J-ROCKET AF22  Rivaroxaban 15 mg once per d 3.3 64 
ROCKET AF24  Rivaroxaban 20 mg once per d 3.5 55 
ENGAGE20  Edoxaban 60 mg once per d 2.8 28 
ARISTOTLE21  Apixaban 5 mg twice per d 2.1 19 
AVERROES19  Apixaban 5 mg twice per d 2.0 14 
Close Modal

or Create an Account

Close Modal
Close Modal